Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia

2.1 Venetoclax (Venclyxto, AbbVie) with obinutuzumab is indicated 'for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 A 112-pack of 100-mg venetoclax tablets costs £4,789.47 (excluding VAT; BNF online, accessed August 2020). The company has a commercial arrangement. This makes venetoclax available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.4 The price of obinutuzumab is £3,312 per 1,000-mg vial (excluding VAT; BNF online, accessed August 2020). Roche has a commercial arrangement. This makes obinutuzumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is Roche's responsibility to let relevant NHS organisations know details of the discount.